Tarlatamab (Imdelltra) is an investigational bispecific T-cell engager (BiTE) immunotherapy being studied for the treatment of certain cancers, particularly small cell lung cancer (SCLC). It works by directing the patient’s T-cells to recognize and attack cancer cells expressing a specific protein called delta-like ligand 3 (DLL3), commonly found in SCLC. Tarlatamab shows promise as a targeted approach to treating aggressive cancers with limited options, and clinical trials are ongoing to evalua
0:33
Tarlatamab (Imdelltra) is an investigational bispecific T-cell engager (BiTE) immunotherapy being studied for the treatment of certain cancers, particularly small cell lung cancer (SCLC). It works by directing the patient’s T-cells to recognize and attack cancer cells expressing a specific protein called delta-like ligand 3 (DLL3), commonly found in SCLC. Tarlatamab shows promise as a targeted approach to treating aggressive cancers with limited options, and clinical trials are ongoing to evalua
201 viewsDec 12, 2024
FacebookDr Vineet Govinda Gupta Oncology
Tarlatamab Mechanism of Action
1:14
Tarlatamab Mechanism of Action
1.9K viewsOct 4, 2024
YouTubePeerView Oncology
Tarlatamab: Mechanism of Action and Clinical Success in Small Cell Lung Cancer │ Pharmacology
4:26
Tarlatamab: Mechanism of Action and Clinical Success in Small Cell Lung Cancer │ Pharmacology
3.1K viewsJun 2, 2024
YouTubePharmacology Insights
Tarlatamab in Combination Therapy: Future Potential for SCLC | OncLive
Tarlatamab in Combination Therapy: Future Potential for SCLC | OncLive
Oct 21, 2024
onclive.com
Efficacy and Impact of Tarlatamab on Clinical Practice | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Efficacy and Impact of Tarlatamab on Clinical Practice | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
6 months ago
targetedonc.com
Amgen?s IMDYLLTRA (Tarlatamab) erhält bedingte Marktzulassung für die Drittlinienbehandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium im Vereinigten Königreich
Amgen?s IMDYLLTRA (Tarlatamab) erhält bedingte Marktzulassung für die Drittlinienbehandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium im Vereinigten Königreich
Jan 6, 2025
marketscreener.com
#cancer #oncology #imdelltra #tarlatamab #bispecificantibody #bispecifictcellengager #bite #lungcancer #smallcelllungcancer #sclc #extensivestagesmallcelllungcancer #essclc #moffitt… | Bichoy Gabra
#cancer #oncology #imdelltra #tarlatamab #bispecificantibody #bispecifictcellengager #bite #lungcancer #smallcelllungcancer #sclc #extensivestagesmallcelllungcancer #essclc #moffitt… | Bichoy Gabra
5 months ago
linkedin.com
1:30
Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC | OncLive
10 months ago
onclive.com
6:00
Tarlatamab: Taking a BiTE at Small Cell Lung Cancer - 2025 Lung Cancer Video Library
497 views9 months ago
YouTubeGlobal Resource for Advancing Cancer Education
Side Effects of Tarlatamab for SCLC and How They Can Be Monitored at Home
315 viewsFeb 21, 2025
vumedi.com
Practice-Changing Approvals in SCLC: Durvalumab Consolidation and Tarlatamab for Relapsed Disease
Jan 6, 2025
vumedi.com
Dr Sands on Updated Efficacy Findings With Tarlatamab in Previously Treated SCLC | OncLive
Oct 10, 2024
onclive.com
ESMO Asia 2023 Insights: "DeLLphi-301 Study - Tarlatamab for Patients With Previously Treated SCLC"
182 viewsJan 3, 2024
vumedi.com
1:11
What does the future hold for T-cell engagers in small cell lung cancer?
13 views5 months ago
YouTubeVJOncology
ESMO 2025 Insights: DeLLphi-304 Phase 3 Study - Tarlatamab vs. Standard Chemo in Patients With Previously Treated SCLC
5 months ago
vumedi.com
2:24
The DLL3-targeting BiTE, tarlatamab, for the treatment of SCLC
1.4K viewsAug 9, 2022
YouTubeVJOncology
Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC | OncLive
10 months ago
onclive.com
3:22
Evaluating Tarlatamab in Recurrent Small Cell Lung Cancer Treatment
8.4K viewsAug 8, 2023
YouTubeASCOcancer
4:42
Treatment Landscape of Extensive Stage Small Cell Lung Cancer: Tarlatamab - 2024 Lung Cancer OncTalk
483 viewsJan 13, 2025
YouTubeGlobal Resource for Advancing Cancer Education
2L SCLC: Tarlatamab Outcomes in DeLLphi-304 Phase 3 Study
4 months ago
vumedi.com
4:21
Tarlatamab: The Immunotherapy Beating Chemotherapy in Small Cell Lung Cancer
155 views8 months ago
YouTubeClarivive MedInsight
2:17
Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC | OncLive
Jun 28, 2024
onclive.com
9:16
SCLC Second-Line Treatment: Tarlatamab - Small Cell Lung Cancer OncInsights 2025-26
175 views3 months ago
YouTubeGlobal Resource for Advancing Cancer Education
ASCO® 2023 Insights: "Randomized Phase 3 DeLLphi-304 Study - Tarlatamab, a DLL3-Targeting BiTE, Compared to Standard of Care in Patients With Relapsed SCLC"
Jul 2, 2023
vumedi.com
6:46
Tarlatamab for Extensive Stage Small Cell Lung Cancer- 2024 Leading Developments in Lung Cancer
379 viewsNov 13, 2024
YouTubeGlobal Resource for Advancing Cancer Education
3:13
Treatment and Management of Small Cell Lung Cancer (SCLC)
58.2K viewsNov 20, 2017
YouTubeYou and Lung Cancer
2:47
Safety analysis of DeLLphi-304: tarlatamab vs chemotherapy in small cell lung cancer
65 views5 months ago
YouTubeVJOncology
9:06
【NEJM發表】小細胞肺癌重大突破！新藥Tarlatamab登場，存活率突破一年，小細胞肺癌治療邁入新紀元！
3.4K views10 months ago
YouTube腫瘤科吳教恩醫師
5:40
ASCO 2025: How a Team Implemented Outpatient Administration of Tarlatamab for SCLC
137 views10 months ago
YouTubeLung Cancers Today
1:19
Exploring tarlatamab in the DeLLphi-301 trial for small cell lung cancer
343 viewsMar 20, 2025
YouTubeVJOncology
See more